UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya

Similar documents
UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya

UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT

UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Frequency of Metabolic Syndrome on Diabetes Mellitus Patients in Surabaya

UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya

MOA: Long acting glucagon-like peptide 1 receptor agonist

J. Basic. Appl. Sci. Res., 4(12) , , TextRoad Publication

Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre

ORIGINAL ARTICLE. Use of Freestyle Libre Pro TM Flash Glucose Monitoring System in Different Clinical Situations at a Diabetes Centre

Insulin Intensification: A Patient-Centered Approach

Peer Review Report. [long acting insulin analogues glargine and detemir]

UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Number of patients: Planned: 403 Randomized: 391 Treated: 390 Efficacy: 363 (Full analysis set) 356 (Per-protocol set)

Setting The setting was outpatient, secondary care. The economic study was carried out in the UK.

UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S

Insulin Initiation and Intensification. Disclosure. Objectives

Is Degludec the Insulin of Tomorrow?

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded

Medium-Term Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Insulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar )

Efficacy/pharmacodynamics: 85 Safety: 89

Sanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes

GLP-1RA and insulin: friends or foes?

Individualising Insulin Regimens: Premixed or basal plus/bolus?

The hallmark of type 2 diabetes mellitus (T2DM) is progressive

premix insulin and DPP-4 inhibitors what are the facts? New Sit2Mix trial provides first global evidence

Diabetes: Three Core Deficits

DIABETES WORKSHOP EMEA Improved treatments : medication for children/adolescents with diabetes mellitus

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

These results are supplied for informational purposes only.

DIABETES WITH PREGNANCY

Bristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium

Setting The setting was primary care. The economic study was carried out in the USA.

Xultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow

Current Trends in Diagnosis and Management of Gestational Diabetes

Sanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018

ADA Analyst Presentation Saturday 9 th June

Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary

No Increased Cardiovascular Risk for Lixisenatide in ELIXA

These results are supplied for informational purposes only.

CONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario. Antonio Ceriello a,b

iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد

Position Statement of ADA / EASD 2012

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection

Soliqua 100/33. (insulin glargine, lixisenatide) New Product Slideshow

Scottish Medicines Consortium

Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials

UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya

REF/2011/11/ CTRI Website URL -

Management of Type 2 Diabetes

Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?

Sponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy

Insulin pumps (CSII): Using Modern technology to communicate with families of children with type 1 diabetes

Diabetes Care Publish Ahead of Print, published online June 1, 2009

COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)

Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control

Studies on impact of diabetes mellitus on tuberculosis in coastal region of Andhra Pradesh

Gestational Diabetes in Resouce. Prof Satyan Rajbhandari (RAJ)

UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1

By Betsy B. Dokken, PhD, NP, CDE. Keywords: diabetes mellitus, insulin analogues, insulin therapy

Switching from insulin glargine to insulin degludec: Safety and efficacy in Colombian adolescents with type 1 diabetes

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference

The first stop for professional medicines advice

Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

Chairman s Rounds, 02/15/2011

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

Akio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka

Clinical Study Synopsis

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Received 10 September 2014; revised 8 October 2014; accepted 3 November 2014

The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO

Clinical Overview of Combination Therapy with Sitagliptin and Metformin

Supplementary Online Content

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

insulin degludec (Tresiba ) is not recommended for use within NHS Scotland.

Charles Darwin University

Insulin analogues Das PP, Datta PG

UNIVERSITAS AIRLANGGA DIREKTORAT PENDIDIKAN Tim Pengembangan Jurnal Universitas Airlangga Kampus C Mulyorejo Surabaya

Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD

Latest Nutritional Guidelines: What s new for practice? Paul Pipe-Thomas Specialist Dietitian

Cost Effectiveness of canagliflozin (Invokana )

Düsseldorf, Germany 24 th February, Response from Bernd Richter, written in his personal capacity, to the

Team-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals

Le incretine: un passo avanti. Francesco Dotta

SCIENTIFIC STUDY REPORT

Transcription:

page 1 / 6

EDITORIAL BOARD EDITORIAL BOARD Patrons Rector, Airlangga University Dean, Airlangga University School of Medicine Director, Dr Soetomo Hospital Surabaya Founder Prof R Soedarso Djojonegoro, MD Chairman Prof Askandar Tjokroprawiro, MD, PhD Vice-Chairman Prof M Sajid Darmadipura, MD Editor-in-Chief Prof Suhartono Taat Putra, MD, MS, PhD Vice Editor-in-Chief Prof Doddy M Soebadi, MD, PhD Senior Editors Prof Soetjipto, MD, MS, PhD Prof Widjoseno Gardjito, MD Prof Rachmat Santoso, MD Prof Benjamin Chandra, MD, PhD Prof R Moeljono Notosoedirdjo, MD, PhD Prof Purnomo Suryohudoyo, MD Prof Soedijono, MD, PhD Prof Dr med Puruhito, MD Prof Eddy Rahardjo, MD, PhD International Editors Prof HJA Mensink, MD, PhD Prof Sangkot Marzuki, MD, PhD Prof Yasuhiko Tomino, MD, PhD Prof Tikki Pangestu, PhD Prof Aw Tar Choon, MBBS, Mmed (Int.Med), MRC FRCPA, MPP Members Prof Djoko Roeshadi, MD, PhD Prof Benjamin P Margono, MD, PhD Prof Moersintowarti B Narendra, MD, MSc Prof Subijanto Marto Sudarmo, MD, PhD Aucky Hinting, MD, PhD R Darmawan Setijanto, DDS, MS, PhD Prof Parwati Setiono Basuki, MD, MSc, DTM&H Maria Yolanda Probohoesodo, MD Agus Darwanto, Drs, MS, PhD Managing Editors page 2 / 6

Suharto MD, MSc, DTM&H, PhD Joewono Soeroso, MD, MSc, PhD Endang Joewarini, MD, PhD Consultants Prof Haryono Suyono, PhD Prof Marsetio Donosepoetro, MD, PhD Prof Karjadi Wirjoatmodjo, MD Prof D Ma rifin Husin, MD, MSc Prof Eddy Soewandojo, MD Triono Soendoro, MD, PhD International Communication Dripa Sjabana, MD, MS Executive Secretaries Sunarko Setyawan, MD, MS, PhD Sri Musta ina, Drs, MS Mochammad Zuhdy, Drs Marketing and Subscription Prof Rochmad Romdoni, MD, PhD Urip Murtedjo, MD Agung Prasmono, MD Poedjo Hartono, MD Fund Raising Prof Boediwarsono, MD Agus Harianto, MD Suhartono DS, MD Treasurer Slamet Soeharto, Ir page 3 / 6

Table of Contents No Title Page 1 THE EFFECTIVENESS OF TOPICAL GARLIC EXTRACT FOR METHICILLIN RESISTANT 72-77 Staphylococcus aureus TREATMENT IN BURNS 2 Mycobacterium tuberculosis IMMUNOGLOBULIN M (IgM) AND IMMUNOGLOBULIN G 78-81 (IgG) SURVEY IN HIV-INFECTED DONORS 3 COMPARING THE EFFECT OF RED YEAST RICE, DATE PALM, AND GUAVA LEAF 82-87 EXTRACT ON THROMBOCYTE AND MEGAKARYOCYTE COUNT IN THROMBOCYTOPENIC WHITE RATS 4 MATERNALLY INHERITED NUCLEOTIDE VARIATION OF MITOCHONDRIAL DNA (mtdna) 88-90 D-LOOP REGION 126 pb (nt: 34-159 HVS II) IN MADURESE INDIVIDUALS 5 RAPID CULTURE METHOD USING BIPHASIC MEDIA ON BACTERIOLOGIC DIAGNOSIS 91-96 TO DETECT Mycobacterium tuberculosis FOR DETERMINING PULMONARY TUBERCULOSIS 6 EFFECT OF CARBIDE AND CaCl2 CONCENTRATION ON VITAMIN C CONTENTS OF 97-100 BANANA KEPOK 7 DIRECT CLONING OF MELANOMA ANTIGEN 1 (MAGE-1) AND THE E2 GENE OF HOG 101 - CHOLERA VIRUS (HCV) FROM THE BLUNT END PCR PRODUCT USING pet 101/D-TOPO 108 8 QUANTITATION OF MICROORGANISMS IN LOWER RESPIRATORY TRACT SECRETIONS 109-111 9 BMD-QUS ASSESSMENT RESULT APPROPRIATES TO DIAGNOSE OSTEOPOROSIS 112-115 10 ACID-FAST BACTERIA M. leprae EXAMINATION IN LEPROSY PATIENTS BEFORE AND AFTER TREATMENT 116-118 11 DIAGNOSTIC ROLE OF INTRA OPERATIVE OVARIAN CYST FLUID CYTOLOGY IN DETERMINING MALIGNANCY 119-123 12 CORRELATION BETWEEN ADOLESCENTS' KNOWLEDGE ON DRUGS HAZARD AND THEIR BEHAVIOR IN DRUG ABUSE IN TULUNGAGUNG 124-127 13 BASAL INSULIN AS ADD-ON THERAPY TO ORAL GLUCOSE-LOWERING DRUGS IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS IN PRIMARY PUBLIC HEALTH CENTER 128-133 page 4 / 6

Vol. 49 - No. 2 / 2013-04 TOC : 13, and page : 128-133 BASAL INSULIN AS ADD-ON THERAPY TO ORAL GLUCOSE-LOWERING DRUGS IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS IN PRIMARY PUBLIC HEALTH CENTER BASAL INSULIN AS ADD-ON THERAPY TO ORAL GLUCOSE-LOWERING DRUGS IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS IN PRIMARY PUBLIC HEALTH CENTER Author : Hermina Novida - Agung Pranoto - Jongky Hendro Prayitno - Askandar Tjokroprawiro - Abstract Effective glycemic control is very important to minimize longterm complications of type 2 diabetes mellitus (DM). However, it is welldocumented that many patients spend prolonged periods above optimal glycaemic range, especially in primary public health centers.most of primary care physicians, who are responsible to manage them, delay to iniate insulin therapy for some reasons. The aim ofthis study was to evaluate efficacy and safety of insulin detemir added to oral therapy in insulin-naive individuals with type 2 DM.This one group pre- and post-test study involved insulin-naive and previously oral-treated DM patients (n=64, HbA1c> 8.0%),drawn from 10 primary public health center centers all over Surabaya, Indonesia, using simple random sampling method. Patientswere treated with insulin detemir for 12 weeks and insulin doses were titrated to target fasting plasma glucose (FPG) < 125 mg/dl.outcomes evaluated included HbA1c, level of fasting and 2 hours post-prandial glucose, risk of hypoglycemia and body weight. After12 weeks, HbA1c had decreased by 2.53% (from 11.38% to 8.85%) with detemir insulin once a day (p=0.001). FPG improved from201.75 mg/dl to 152.47 mg/dl (p=0.001) and 2 hour post-prandial glucose improved from 287.91 mg/dl to 222.30 mg/dl (p=0.001).frequency of hypoglycaemia events were 6.4% (4 hypoglycaemic events) and all cases were mild events so that they did not need tobe admitted in the hospital. Hypoglycaemic events can be treated by the patients themselves with sugar and food intake, and then thedose of detemir insulin was adjusted. Besides hypoglyecemic events, no other side effects were recorded. Mean the pre insulintherapy BMI was 23.94 ± 4.22 kg/m2 to become 23.34 ± 5.60 kg/m 2 at the end of the study. There was a decrease in body weightbefore and after insulin detemir therapy, but it was not statistically significant (p 0.37, 95% CI -0.74-1.95). In conclusion, theaddition of basal insulin to oral antidiabetic drugs in poorly controlled type 2 diabetes patients in primary public health centerachieved clinically improvements in glycaemic control with low risks of hypoglycaemia and non-significant body weightincrease.(fmi 2013;49:128-133) Keyword : basal, insulin, add-on, therapy, oral, antidiabetics, glycaemia, type, 2, Daftar Pustaka : 1. Hermansen K, Lund P, Clemmensen K, Breum L, Moller KM, Rosenfalk AM, (2007). 3-months results from denmark within the globally prospective and observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes: The PREDICTIVE Study. - : The Review of Diabetes Study 2. Hirsch IB, Bergenstal RM, Parkin CG, Wright Jr E, Buse JB, (2005). A real world approach to insulin therapy in primary care practice. - : Clin Diabetes page 5 / 6

Powered by TCPDF (www.tcpdf.org) UNIVERSITAS AIRLANGGA Copy alamat URL di bawah ini untuk download fullpaper : journal.unair.ac.id/filerpdf/fmi5887bc14e8full.pdf page 6 / 6